# HS-20117

Source: https://onco.cc/drugs/hs-20117/  
OnCo record `hs-20117` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HS-20117 is an experimental bispecific antibody from Hansoh BioMedical R&D in phase 3 trials for non-small-cell lung cancer, aimed at EGFR and MET.

## Summary

HS-20117 (PM1080) is a bispecific antibody developed by Hansoh BioMedical R&D. Its targets are EGFR and MET (the sponsor names EGFR x MET). The sponsor states: A fully-human EGFR-MET IgG1-like bispecific antibody. ClinicalTrials.gov describes the intervention as: Participants will receive HS-20117 once during cycle 1 and once every 2 weeks during subsequent cycles (The duration of each treatment cycle is 28 days). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06417008 (A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer), in non-small-cell lung cancer. The largest, NCT06417008, plans to enrol 1080 participants with primary completion was scheduled for 2026-06-01 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: PM1080
- Modality: bispecific antibody
- Mechanism: A fully-human EGFR-MET IgG1-like bispecific antibody.

## Sources

- ClinicalTrials.gov: trials of HS-20117: https://clinicaltrials.gov/search?intr=PM1080

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [EGFR](https://onco.cc/targets/egfr/), [MET](https://onco.cc/targets/met/)
- companies: [Hansoh Pharmaceutical](https://onco.cc/companies/hansoh-pharma/)
- trials: [A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06417008/)

---
JSON: https://onco.cc/api/v1/entities/hs-20117.json